AAAseem Anand

Aseem Anand

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aseem Anand has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).

    by Andrew J. Armstrong, Lars Edenbrandt, Eva Bondesson, Aseem Anand, Orjan Nordle, Michael Anthony Carducci, Michael J. Morris

    5006 Background: Quantitative measures of metastatic bone disease are needed in men with mCRPC. We recently demonstrated the validity/reproducibility of a computational approach to bone scan imaging that employs artificial intelligence called the automated BSI (aBSI), which quantifies the percent of skeletal mass involved by cancer. We aimed to extend the prognostic validation of aBSI in a multinational prospective phase 3 clinical study of men with bone-metastatic CRPC. Methods: Whole-body bone scans were acquired at screening in a placebo-controlled phase 3 trial of men with mCRPC and bone metastases and treated with tasquinimod/placebo (n = 1,245). The prospective aBSI biomarker analysis plan was locked in Sept 2014 prior to treatment unblinding. All scans generated at 241 trial sites in 37 countries were assessed for image quality and analyzed using the EXINI boneBSI v.2 software and were blindly associated with outcomes. Baseline aBSI was evaluated for its independent prognostic association with overall survival (OS), radiographic progression-free survival (rPFS), and symptomatic skeletal related events (SSEs). Results: The aBSI-population (721 pts) was representative of the entire trial population based on patient characteristics at screening and OS outcomes. Median aBSI was 1.07 (SE 0.05). The aBSI-population was divided into quartiles (n = 180-181) with aBSI-levels of 0 - 0.3 (Q1); > 0.3 - 1.1 (Q2); > 1.1 - 4.0 (Q3); and > 4.0 (Q4) and median OS ranging from 35 months (Q1) to 13 mo (Q4) (p < 0.0001). Baseline aBSI was significantly associated with OS (HR 1.2 per doubling of BSI; p < 0.0001) and remained independently associated with OS after adjustment for treatment, PSA, CRP, LDH and albumin. Baseline aBSI was also strongly associated with rPFS (p = 0.0005), time to symptomatic progression (p < 0.0001), and time to SSE (p = 0.001). Conclusions: This analysis represents the first phase 3 evaluation of aBSI as a clinically validated prognostic biomarker for OS, rPFS, and SSEs in men with bone-metastatic CRPC, providing independent prognostic information over commonly measured clinical characteristics. Clinical trial information: NCT01234311.


  • Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC).

    by Aseem Anand, Anders Bjartell, Daniel Costin Danila, Danny Francisco Martinez, Lars Edenbrandt, Steven M. Larson, Howard I. Scher, Michael J. Morris

    170 Background: PCWG2 radiographic progression criteria, which are associated with survival, rely on lesion counting. There is a need for a fully quantitative assessment of tumor burden as a component of a true response biomarker for mCRPC. Here, we used the bone scan index (BSI) to fully quantitate the increase in skeletal disease burden at each radiographic milestone that constitutes the PCWG2 criteria. Methods: mCRPC patients (pts) from clinical trials using PCWG2 criteria to determine progression (PD) were assessed. Pts were required to have baseline (BL) and at least two follow-up (FU) bone scans. The EXINI automated platform was used to generate BSI at key PCWG2 landmarks: 2+2 criteria for early PD and post flare PD criteria with the appearance of 1 and ≥2 new lesions. Median (M) and Interquartile range (IQR) of the relative change in BSI were calculated to quantify the increase in total tumor burden. Results: A total of 257 pts were assessed, of whom 169 had two or more FU bone scans at 8 or 12 week intervals. Of the total 169 pts, 86 (51%, 95%CI 43-58) met PD by PCWG criteria. 35 (41%, 95%CI 31-51) of 86 pts met the early PD criteria, the remaining 51 (59%, 95%CI 49-69) met PD at subsequent time points after flare period. The ability of the automated platform to reproduce a BSI value, retrieved from the same scan, was highly consistent (100%). The relative BSI increase during the course of meeting PD by PCWG2 is shown in the Table. Conclusions: This is the first quantitative assessment of changes in total tumor burden in pts meeting PCWG2 criteria. Relative changes in BSI can be substantial in meeting the criteria. These data build on the PCWG2 criteria by quantitating the increase both of existing lesions and the contribution of new lesions. We are now assessing the associations with survival that these incremental increases represent. [Table: see text]


  • Automated bone scan index as an imaging biomarker in metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223.

    by Aseem Anand, Stephanie Daignault, Luke T. Nordquist, Jorge Ramos, Rohit K. Jain, Matthew McDonald, Gregory Campbell, Saby George, Costantine Albany, Evan Y. Yu, et al.

    E16600 Background: There are no validated imaging tools to assess response to the Radium-223 (Ra 223). In this study, we explored the analytically validated automated bone scan index (auto-BSI) as an imaging biomarker in mCRPC Patients (Pts) treated with Ra-223. Methods: In a multi-center retrospective study, available bone scans of mCRPC Pts treated with Ra 223, were collected at baseline (BL) and at treatment follow-up (Tx-FU). The auto-BSI was analyzed using the EXINIboneBSI version 2. Logistic regression, cox regression and Kaplan Meier analyses evaluated the auto-BSI associations with PSA response, defined as 50% decline from BL; pain response, defined as decrease in the VAS score from BL; Alkaline phosphatase (ALP) response, defined as 30% decline from BL; and with overall survival (OS). Results: Of144 Pts treated with Ra223, 66 (46%) had a BL bone scan and 25 of them also had a Tx-FU bone scan taken 18 to 30 weeks after the first treatment. No significant differences were observed in BL characteristics of Pts with bone scans versus without. The median number of ra223 doses were 6 (1-6). Median BL auto-BSI was 2.4 (range:0.01–33.2) and median Tx-FU auto-BSI was 0.5 (range:0-20.1). The BL auto-BSI was associated with OS (HR = 1.4; 95%CI = 1.1-2.0) and with ALP response (HR = 1.6; 95%CI = 1.04-2.4), p = 0.02. BL auto-BSI was not associated with pain, p = 0.48, or with PSA response, p = 0.76. OS at 9 months with BL auto-BSI < 5 was 76% vs. 40% in Pts with BSI > 5. In Tx-FU analysis, 17 (68%) of the 25 Pts had ≥ 30% decrease in auto-BSI from BL; Only 5 (20%) Pts were PSA responders, and all 5 Pts had ≥ 30% decrease in auto-BSI. Conclusions: Baseline auto-BSI was associated with OS and with ALP response. The findings encourage prospective investigations to validate the role of BSI as an imaging biomarker in mCRPC Pts being treated with Ra-223.

  • Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC).

    by Aseem Anand, Michael J. Morris, Steven M. Larson, Mattias Ohlsson, Andreas Joseffson, John Thomas Helgstrand, Lars Edenbrandt, Peter Sander Oturai, M. Andreas Roeder, Anders Bjartell

    226 Background: The automated BSI (auto-BSI) is a computerized means of quantitatively expressing tumor burden in bone. Following the analytical validation of auto-BSI, we are now clinically qualifying the tool as a response biomarker in mCRPC. In the present study, we assess the association of auto-BSI and that of PSA with overall survival (OS) in mCRPC patients (pts) being treated with enzalutamide. Methods: All mCRPC pts who initiated enzalutamide treatment at Skåne Hospital, Sweden and at Rigshospitalet, Denmark, with a minimum of one year follow-up, were eligible for the study. Eligible mCRPC pts with baseline (BL) bone scan available before starting enzalutamide were enrolled in the study. PSA, hemoglobin (Hgb) and alkaline phosphatase (ALP) were obtained at BL. Treatment follow-up PSA and auto-BSI were obtained at week-12. auto-BSI was obtained using the analytically validated EXIN boneBSIversion 2.0. Cox regression and concordance index (c-index) were used to evaluate the association with OS. Results: 80 mCRPC pts with BL bone scans were enrolled in the study. Treatment follow-up bone scans were available from 62 pts. Univariate analysis demonstrated that auto-BSI, PSA, ALP and Hgb at BL were associated with OS (p < 0.0001). In the multivariate analysis, only auto-BSI and HgB were significantly associated with OS. The auto-BSI showed the highest c-index in prediction of OS (c-index 0.72, SE 0.03). Adding auto-BSI to the BL covariate model significantly improved the discrimination from c-index 0.67 to 0.72 (p < 0.05). At treatment follow-up, the univariate analysis of the change in auto-BSI and the percent change in PSA were strongly associated with OS with c-index 0.76 and 0.72 (SE 0.05), respectively. In bivariate analysis, the change in auto-BSI remained strongly associated with OS (p < 0.0001) whereas the percent change in PSA appeared to be less so (p = 0.07). Conclusions: Auto-BSI and its change demonstrated an independent and a strong association with OS in mCRPC pts being treated with enzalutamide. The study serve as a foundation for prospective validation of auto-BSI as an imaging biomarker indicative of efficacy to enzalutamide.

  • Bone scan index as a biomarker to predict outcome in real-life mCRPC patients on abiraterone acetate: A multicenter study.

    by Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck Lissbrant, Jan-Erik Damber, Lars Budäus, Till Eichenauer, Per Wollmer, Lars Edenbrandt, et al.

    217 Background: Bone Scan Index (BSI) is a quantitative measurement that reflects the tumor burden in bone calculated from bone scintigraphy. It also represents a prognostic marker in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Abiraterone acetate (AA) has showed to prolong survival before and after chemotherapy in this group of pts. In this study we evaluated the predictive value of BSI change as a biomarker of response in mCRPC patients on treatment with AA. Methods: We retrospectively studied 62 mCRPC pats who received AA following disease progression after chemotherapy at 3 different academic hospitals. Automated baseline and follow-up BSI data was obtained from images of whole-body bone scintigraphies performed before and during AA treatment. Data on clinical overall survival (OS), blood levels of prostate-specific antigen (PSA), alkaline phosphatase (ALP) and haemoglobin (Hb) at the time of baseline and upon follow-up was collected from medical records. The association between changes in these parameters at follow-up and survival was evaluated using Cox proportional-hazards regression models and Kaplan-Meier estimates of the survival function. Discrimination between prognostic variables was assessed using the concordance index (C-index). Results: Pts with an increase in BSI of > 0.3 (n=31) had 13% one year-survival rate compared to 42% for pts with improvement or stable disease according to BSI change at follow-up (BSI change < 0.3; n=31) (p< 0.001). Among all parameters evaluated (BSI, PSA, ALP, Hb) in a univariate Cox analysis, BSI change from baseline to follow-up presented the highest and strongest association with OS (C-index=0.7, Hazard ratio= 1.3 and p=0.0001). Conclusions: Increase in BSI of ≥ 0.3 is significantly associated with reduced survival in mCRPC pts under AA treatment following disease progression in a post-chemotherapy setting. BSI is a candidate biomarker to evaluate response and survival in this group, and change in BSI could be a valuable tool in monitoring pts with mCRPC on second-line therapies. BSI could then serve as a decision making tool supporting physicians to continue current treatment or to consider alternative therapies.